Tenpoint Therapeutics and Visus Therapeutics Complete Merger to Advance Ophthalmic Pipeline
December 12, 2024
Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. completed a merger to combine their ophthalmic drug development programs, bringing the late-stage presbyopia candidate BRIMOCHOL PF together with Tenpoint’s broader aging-eye pipeline. The combined company is launching a crossover financing round with participation from institutional investors to support an NDA filing and a planned US commercial launch of BRIMOCHOL PF in the 1H of 2026. Henric Bjarke was named CEO of the merged company.
- Buyers
- Tenpoint Therapeutics Limited
- Targets
- Visus Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Washington, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Grundium Acquires Visiopharm
May 25, 2026
AI & Machine Learning
Grundium announced it has acquired Visiopharm to create an integrated precision pathology platform that combines digital slide scanning with AI-driven pathology software. The combined offering is intended to support diagnostic laboratories, biopharmaceutical development, and research organizations with more scalable, cost-effective digital pathology workflows, including biomarker assessment and clinical research use cases.
-
Lupin Acquires VISUfarma from GHO Capital
September 29, 2025
Healthcare Services
Lupin Limited, through its wholly owned subsidiary Nanomi B.V., signed a definitive agreement to acquire VISUfarma B.V. from healthcare investor GHO Capital Partners LLP. The acquisition expands Lupin’s specialty ophthalmology franchise by adding a portfolio of 60+ branded eye health products and established commercial operations across major European markets.
-
Visiox Pharmaceuticals Announces Definitive Merger With Ocuvex Therapeutics
August 19, 2024
Healthcare Services
Visiox Pharmaceuticals, Inc. entered into a definitive merger agreement with Ocuvex Therapeutics, Inc., an ophthalmic pharmaceutical company focused on developing and commercializing therapies for glaucoma and other eye disorders. The combined company will operate under the Ocuvex name, aiming to strengthen its ophthalmic portfolio and accelerate commercialization of near-term products.
-
Vistagen Acquires Pherin Pharmaceuticals
December 21, 2022
Biotechnology
Vistagen (Nasdaq: VTGN) will acquire Pherin Pharmaceuticals in an all-stock transaction (approximately 12.4 million shares plus nominal cash), giving Vistagen full ownership of Pherin's pherine drug pipeline and intellectual property. The deal eliminates future royalty and milestone obligations related to PH94B and PH10 and adds three early-stage pherine candidates to Vistagen's development portfolio.
-
Ares Management Acquires Majority Stake in Point Vision; Bpifrance Takes Minority Stake
October 12, 2021
Healthcare Services
Funds managed by the Private Equity Group of Ares Management acquired a majority stake in Point Vision, the French network of ophthalmology centers, while Bpifrance took a minority stake. The founders and key professionals are reinvesting as Point Vision plans to continue rolling out new centers across France and expand its services including teleconsultation and additional surgical specialties.
-
Hilco Vision Acquires Bruder Healthcare
September 17, 2021
Medical Devices
Hilco Vision, a portfolio company of Windjammer Capital Investors, has acquired Bruder Healthcare effective September 17, 2021; terms were not disclosed. Bruder, a maker of therapeutic and ophthalmic dry-eye products based in Alpharetta, Georgia, will be integrated into Hilco’s product portfolio as the transaction represents a PE-backed add-on to expand Hilco’s offerings to eye care professionals and consumers.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.